Disc Medicine (NASDAQ:IRON) Now Covered by Analysts at TD Cowen

TD Cowen initiated coverage on shares of Disc Medicine (NASDAQ:IRON) in a report issued on Thursday, MarketBeat.com reports. The firm issued a buy rating on the stock.

IRON has been the subject of several other reports. Stifel Nicolaus increased their price objective on Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a research note on Friday, January 24th. HC Wainwright reaffirmed a “buy” rating and set a $118.00 price objective on shares of Disc Medicine in a research report on Tuesday, January 21st. Raymond James raised shares of Disc Medicine from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $66.00 to $110.00 in a research note on Monday, November 4th. Morgan Stanley upgraded Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price target for the company in a report on Tuesday, November 5th. Finally, Wedbush reissued an “outperform” rating and issued a $90.00 target price (up from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Disc Medicine has an average rating of “Buy” and an average target price of $88.90.

Disc Medicine Stock Up 0.1 %

Shares of NASDAQ IRON opened at $54.50 on Thursday. The business has a fifty day simple moving average of $58.25 and a 200-day simple moving average of $55.44. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -13.69 and a beta of 0.73. Disc Medicine has a 12 month low of $25.60 and a 12 month high of $77.60.

Disc Medicine (NASDAQ:IRON) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.08. As a group, sell-side analysts expect that Disc Medicine will post -4.07 EPS for the current fiscal year.

Insider Activity at Disc Medicine

In other news, insider Pamela Stephenson sold 3,137 shares of Disc Medicine stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $171,217.46. Following the sale, the insider now directly owns 69,529 shares in the company, valued at approximately $3,794,892.82. The trade was a 4.32 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John D. Quisel sold 12,791 shares of the stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $66.01, for a total transaction of $844,333.91. Following the completion of the transaction, the chief executive officer now directly owns 72,065 shares of the company’s stock, valued at $4,757,010.65. This trade represents a 15.07 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 76,037 shares of company stock worth $4,650,001 in the last ninety days. 4.24% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Disc Medicine

Institutional investors have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new position in shares of Disc Medicine during the 4th quarter worth approximately $40,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Disc Medicine by 399.2% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 93,103 shares of the company’s stock valued at $5,903,000 after acquiring an additional 74,454 shares during the period. Woodline Partners LP boosted its stake in shares of Disc Medicine by 5.2% in the 4th quarter. Woodline Partners LP now owns 396,600 shares of the company’s stock valued at $25,144,000 after purchasing an additional 19,538 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Disc Medicine by 26.5% in the 4th quarter. ProShare Advisors LLC now owns 6,966 shares of the company’s stock worth $442,000 after purchasing an additional 1,458 shares during the last quarter. Finally, MPM Bioimpact LLC increased its position in shares of Disc Medicine by 11.1% during the 4th quarter. MPM Bioimpact LLC now owns 346,401 shares of the company’s stock worth $21,962,000 after purchasing an additional 34,640 shares in the last quarter. 83.70% of the stock is owned by institutional investors and hedge funds.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.